PURPOSE: Insulin-like growth factor 1 (IGF-1) levels are positively related to some cancers and negatively related to cardiovascular disease. These conditions are also related to insulin resistance and high body weight, leading to the hypothesis that IGF-1 levels may, in part, mediate the association of high body weight with these health outcomes. Using the National Health and Nutrition Examination Survey (NHANES) III population, we examined the associations between IGF-1, IGF binding protein-3 (IGFBP-3), and the IGF-1/IGFBP-3 molar ratio with anthropometric measures in a large, U.S. population-based study where these associations could also be stratified by race/ethnicity and gender. METHODS: The study population consisted of 3,168 women and 2,635 men (44% non-Hispanic white, 28.2% non-Hispanic black, and 27.7% Mexican-American). Anthropometric measures were obtained by trained personnel in the NHANES mobile examination centers. IGF-1 and IGFBP-3 were measured using immunoassays by staff at Diagnostic System Laboratories (DSL) Inc. (Webster, TX). Associations of IGF-1, IGFBP-3, and IGF-1/IGFBP-3 molar ratio with anthropometric variables across race/ethnicity and gender were evaluated by using linear regression modeling. RESULTS: Body mass index (BMI) was inversely associated with IGF-1 levels across all of the race/ethnicity and gender subgroups. In contrast, BMI, waist to hip ratio (WHR), and waist circumference were positively associated with IGFBP-3 levels only in non-Hispanic black men and non-Hispanic white women. The IGF-1/IGFBP-3 molar ratio was inversely associated with all anthropometric measures, except height, in all subgroups of the population. CONCLUSION: The significant inverse associations of BMI with IGF-1 levels and of all anthropometric variables, except height, with the IGF-1:IGFBP-3 molar ratio in all subgroups do not support existing hypotheses that associations of excess weight with negative health outcomes, such as specific cancer diagnoses, are mediated through high IGF-1 levels.
PURPOSE:Insulin-like growth factor 1 (IGF-1) levels are positively related to some cancers and negatively related to cardiovascular disease. These conditions are also related to insulin resistance and high body weight, leading to the hypothesis that IGF-1 levels may, in part, mediate the association of high body weight with these health outcomes. Using the National Health and Nutrition Examination Survey (NHANES) III population, we examined the associations between IGF-1, IGF binding protein-3 (IGFBP-3), and the IGF-1/IGFBP-3 molar ratio with anthropometric measures in a large, U.S. population-based study where these associations could also be stratified by race/ethnicity and gender. METHODS: The study population consisted of 3,168 women and 2,635 men (44% non-Hispanic white, 28.2% non-Hispanic black, and 27.7% Mexican-American). Anthropometric measures were obtained by trained personnel in the NHANES mobile examination centers. IGF-1 and IGFBP-3 were measured using immunoassays by staff at Diagnostic System Laboratories (DSL) Inc. (Webster, TX). Associations of IGF-1, IGFBP-3, and IGF-1/IGFBP-3 molar ratio with anthropometric variables across race/ethnicity and gender were evaluated by using linear regression modeling. RESULTS: Body mass index (BMI) was inversely associated with IGF-1 levels across all of the race/ethnicity and gender subgroups. In contrast, BMI, waist to hip ratio (WHR), and waist circumference were positively associated with IGFBP-3 levels only in non-Hispanic black men and non-Hispanic white women. The IGF-1/IGFBP-3 molar ratio was inversely associated with all anthropometric measures, except height, in all subgroups of the population. CONCLUSION: The significant inverse associations of BMI with IGF-1 levels and of all anthropometric variables, except height, with the IGF-1:IGFBP-3 molar ratio in all subgroups do not support existing hypotheses that associations of excess weight with negative health outcomes, such as specific cancer diagnoses, are mediated through high IGF-1 levels.
Authors: P Stattin; A Bylund; S Rinaldi; C Biessy; H Déchaud; U H Stenman; L Egevad; E Riboli; G Hallmans; R Kaaks Journal: J Natl Cancer Inst Date: 2000-12-06 Impact factor: 13.506
Authors: E A Platz; M N Pollak; E B Rimm; N Majeed; Y Tao; W C Willett; E Giovannucci Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-12 Impact factor: 4.254
Authors: E Giovannucci; M N Pollak; E A Platz; W C Willett; M J Stampfer; N Majeed; G A Colditz; F E Speizer; S E Hankinson Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-04 Impact factor: 4.254
Authors: Andrew G Renehan; Marcel Zwahlen; Christoph Minder; Sarah T O'Dwyer; Stephen M Shalet; Matthias Egger Journal: Lancet Date: 2004-04-24 Impact factor: 79.321
Authors: S Savastano; A Barbato; C Di Somma; B Guida; G Pizza; L Barrea; S Avallone; M Schiano di Cola; P Strazzullo; A Colao Journal: J Endocrinol Invest Date: 2012-07-09 Impact factor: 4.256
Authors: Kristine M Erlandson; Suzanne P Fiorillo; Sandra Wagner Cardoso; Cynthia Riviere; Jorge Sanchez; James Hakim; Nagalingeswaran Kumarasamy; Sharlaa Badal-Faesen; Umesh Lalloo; Johnstone Kumwenda; Thomas B Campbell; Todd T Brown Journal: AIDS Res Hum Retroviruses Date: 2017-05-16 Impact factor: 2.205
Authors: Stefania I Papatheodorou; Sabine Rohrmann; David S Lopez; Gary Bradwin; Corinne E Joshu; Norma Kanarek; William G Nelson; Nader Rifai; Elizabeth A Platz; Konstantinos K Tsilidis Journal: Cancer Causes Control Date: 2014-01-07 Impact factor: 2.506
Authors: Shauna S Runchey; Edward J Boyko; George N Ioannou; Kristina M Utzschneider Journal: J Gastroenterol Hepatol Date: 2014-03 Impact factor: 4.029
Authors: Adana A Llanos; Theodore M Brasky; Ramona G Dumitrescu; Catalin Marian; Kepher H Makambi; Bhaskar V S Kallakury; Scott L Spear; David J Perry; Rafael J Convit; Mary E Platek; Lucile L Adams-Campbell; Jo L Freudenheim; Peter G Shields Journal: Breast Cancer Res Treat Date: 2013-03-02 Impact factor: 4.872
Authors: Sarah S Comstock; Diana Xu; Kari Hortos; Bruce Kovan; Sarah McCaskey; Dorothy R Pathak; Jenifer I Fenton Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-06-24 Impact factor: 4.254
Authors: S Rinaldi; C Biessy; M Hernandez; F Lesueur; I dos-Santos-Silva; M S Rice; M Lajous; R Lopez-Ridaura; G Torres-Mejía; I Romieu Journal: Int J Cancer Date: 2013-10-05 Impact factor: 7.396
Authors: Hannah Oh; Ruth M Pfeiffer; Roni T Falk; Hisani N Horne; Jackie Xiang; Michael Pollak; Louise A Brinton; Anna Maria V Storniolo; Mark E Sherman; Gretchen L Gierach; Jonine D Figueroa Journal: Int J Cancer Date: 2018-04-01 Impact factor: 7.396
Authors: Amani M Norling; Adam T Gerstenecker; Thomas W Buford; Bilal Khan; Suzanne Oparil; Ronald M Lazar Journal: Geroscience Date: 2019-12-05 Impact factor: 7.713